Claire Presswood
Internal Medicine · Morehead City, NCNPI 1730525932
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $3,455 of the $5,505 with a category attached, or 62.8%. 18 manufacturers reported payments, led by Boehringer Ingelheim International GmbH at 29.6% of the total. Among internal medicine clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 76 payments — averaging $72.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$2K
- Zealand Pharma A/s$2K
- Boehringer Ingelheim$1K
- Novo Nordisk$314
- Amgen$95
- Lilly USA, LLC$81
- plus $476 from 12 others
Across 316 payments — averaging $8772.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1M
- Boehringer Ingelheim$504K
- Novavax Inc$316K
- AstraZeneca$277K
- Sanofi Pasteur Inc.$200K
- Madrigal Pharmaceuticals$182K
- plus $267K from 2 others
What the payments were for
- Travel & lodging$3,45563%
- Food & beverage$2,05037%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 11 | $1,629 |
| Zealand Pharma A/s | 2 | $1,525 |
| Boehringer Ingelheim | 12 | $1,384 |
| Novo Nordisk | 14 | $314 |
| Amgen | 5 | $95 |
| Lilly USA, LLC | 2 | $81 |
| Tandem Diabetes Care, Inc. | 4 | $72 |
| Pfizer | 5 | $70 |
| AstraZeneca | 4 | $64 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $49 |
| Sanofi-aventis U.S. LLC | 2 | $42 |
| Teva Pharmaceuticals USA, Inc. | 3 | $35 |
| AbbVie | 2 | $34 |
| Sanofi Pasteur Inc. | 2 | $27 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| Rhythm Pharmaceuticals, Inc. | 1 | $23 |
| Sequel Med Tech, LLC | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Saxenda$109
How this compares
$5,505 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 160 | $249,788 |
| MounjaroTirzepatide | 75 | $104,610 |
| JardianceEmpagliflozin | 49 | $70,482 |
| TrulicityDulaglutide | 36 | $52,400 |
| JanuviaSitagliptin Phosphate | 40 | $48,168 |
| RybelsusSemaglutide | 19 | $43,554 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 21 | $22,020 |
| FarxigaDapagliflozin Propanediol | 14 | $18,795 |
| Xigduo XrDapaglifloz Propaned/Metformin | 19 | $18,674 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $18,572 |
| Tresiba Flextouch U-100Insulin Degludec | 18 | $14,645 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $10,938 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 25 | $10,782 |
| TradjentaLinagliptin | 13 | $10,597 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $9,422 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $314 | $293,341179 claims |
| Lilly USA, LLCMounjaro, Trulicity | $81 | $157,011111 claims |
| Boehringer IngelheimJardiance, Tradjenta | $1,384 | $81,07962 claims |
| AstraZenecaFarxiga | $64 | $18,79514 claims |
| AbbVieSynthroid | $34 | $8,26499 claims |
| PfizerLevoxyl | $70 | $40611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Morehead City
- Nirmish ShahDurham$862K
- Eugene WrightFayetteville$839K
- Saad UsmaniCharlotte$551K
- Bhakti PaulRaleigh$536K
- Mary KlotmanDurham$478K
- Manesh PatelDurham$435K
- Millie LongChapel Hill$374K
- Marc JohnsonCharlotte$342K
- Christina CraterRaleigh$330K
- Jamy ArdWinston Salem$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.